Volume 30, Issue 143 (November & December 2022)                   J Adv Med Biomed Res 2022, 30(143): 519-535 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Khoshnegah Z, Keramati M R, Taraz Jamshidi S, Karimi-Shahri M, Boroumand-Noughabi S. Association between Laboratory Findings and Mortality of Hospitalized Patients with Covid-19 in Mashhad, Iran. J Adv Med Biomed Res 2022; 30 (143) :519-535
URL: http://journal.zums.ac.ir/article-1-6700-en.html
1- Dept. of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2- Dept. of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3- Dept. of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran , boroumands@mums.ac.ir
Abstract:   (30570 Views)

Background and Objective: COVID-19 has enforced high burden on health systems universally. To better allocate limited health equipment, we aimed to investigate the prognostic impacts of laboratory parameters.
Materials and Methods: All SARS-CoV-2 patients admitted to Imam-Reza University Hospital, Mashhad, Iran, during three COVID19 peak periods in Iran (March to April 2020, July to August, and October to November 2020) were enrolled the study. Demographic and laboratory data were extracted and compared between survivors and non-survivors. Regression analyses and receiver operating characteristic (ROC curve) were used to identify risk factors and assess the ability of laboratory tests in predicting in-hospital mortality.
Results: A total of 2156 COVID19 patients were included in the analysis, with a mean age of 60.20 (±18.8) years. Most patients were male (57%). Multiple regression analysis identified older age (OR=1.01), male sex (OR=2.34), lymphopenia (OR=2.12), LDH >500U/L (OR=2.17), hypernatremia (OR=9.7), urea >45mg/dL (OR=3.6), and BS >200mg/dl (OR=1.93) as significant risk factors for in-hospital death. Using ROC curve analysis, D-dimer (>1000ng/ml) as well as CK-Mb (>28U/L) both with sensitivities and specificities of more than 80% and PPV of about 90% were able to identify patients with higher possibility of in-hospital death.
Conclusion: Male sex, older age, lymphopenia, hypernatremia, increased Urea, increased LDH, and hyperglycemia may serve as potential risk factors for in-hospital death. D-dimer and CK-MB may be used in identifying patients with high probability of in-hospital death. These tests may be used in clinical decision-making in order to improve outcomes of patients with COVID-19.

Full-Text [PDF 712 kb]   (17575 Downloads) |   |   Full-Text (HTML)  (987 Views)  

 Male sex, older age, lymphopenia, hypernatremia, increased Urea, increased LDH, and hyperglycemia may serve as potential risk factors for in-hospital death. D-dimer and CK-MB may be used in identifying patients with high probability of in-hospital death. These tests may be used in clinical decision-making in order to improve outcomes of patients with COVID-19.


Type of Study: Original Research Article | Subject: Clinical Medicine
Received: 2021/09/5 | Accepted: 2022/07/9 | Published: 2022/10/10

References
1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet (London, England). 2020;395(10223):470-3 [DOI:10.1016/S0140-6736(20)30185-9]
2. De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nature Rev Microbiol. 2016;14(8):523-34. [DOI:10.1038/nrmicro.2016.81] [PMID] [PMCID]
3. Liu S, Luo H, Wang Y, et al. Clinical characteristics and risk factors of patients with severe COVID-19 in Jiangsu province, China: a retrospective multicentre cohort study. BMC Infect Disease. 2020;20(1):1-9. [DOI:10.1186/s12879-020-05314-x] [PMID] [PMCID]
4. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. [DOI:10.1016/j.jaut.2020.102433] [PMID] [PMCID]
5. Ji P, Zhu J, Zhong Z, et al. Association of elevated inflammatory markers and severe COVID-19: A meta-analysis. Med. 2020;99(47). [DOI:10.1097/MD.0000000000023315] [PMID] [PMCID]
6. Ou M, Zhu J, Ji P, Li H, Zhong Z, Li B, et al. Risk factors of severe cases with COVID-19: a meta-analysis. Epidemiol Infect. 2020;148:e175. [DOI:10.1017/S095026882000179X] [PMID] [PMCID]
7. Asghar MS, Khan NA, Haider Kazmi SJ, Ahmed A, Hassan M, Jawed R, et al. Hematological parameters predicting severity and mortality in COVID-19 patients of Pakistan: a retrospective comparative analysis. J Community Hosp Intern Med Perspect. 2020;10(6):514-20. [DOI:10.1080/20009666.2020.1816276] [PMID] [PMCID]
8. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Disease. 2020;34:101623. [DOI:10.1016/j.tmaid.2020.101623] [PMID] [PMCID]
9. Goshayeshi L, Akbari Rad M, Bergquist R, Allahyari A, Hashemzadeh K, Hoseini B. Demographic and clinical characteristics of severe Covid-19 infections: a cross-sectional study from Mashhad University of Medical Sciences, Iran. BMC Infect Disease. 2021;21(1):1-8. [DOI:10.1186/s12879-021-06363-6] [PMID] [PMCID]
10. Sobhani S, Aryan R, Kalantari E, et al. Association between clinical characteristics and laboratory findings with outcome of hospitalized COVID-19 patients: a report from Northeast Iran. Interdiscip Perspect Infect Dis. 2021;2021:5552138. [DOI:10.1155/2021/5552138] [PMID] [PMCID]
11. Vahidian F, Najafi S, Khaze Shahgoli V, et al. Determining the clinical and experimental findings of people with COVID-19. Biom Biostat Int J. 2021;10(2):68-73.
12. Lee JS, Kim NY, Na SH, Youn YH, Shin CS. Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea. Med. 2018; 97(26). [DOI:10.1097/MD.0000000000011138] [PMID] [PMCID]
13. Hu L, Chen S, Fu Y, et al. Risk factors associated with clinical outcomes in 323 coronavirus disease 2019 (COVID-19) hospitalized patients in Wuhan, China. Clin Infect Disease. 2020;71(16):2089-98. [DOI:10.1093/cid/ciaa539] [PMID] [PMCID]
14. Guan Wj, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New Eng J Med. 2020;382(18):1708-20. [DOI:10.1056/NEJMoa2002032] [PMID] [PMCID]
15. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Disease. 2020;71(15):769-77. https://doi.org/10.1093/cid/ciaa272 [DOI:10.1093/cid/ciaa225] [PMID] [PMCID]
16. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;75(7):1730-41. [DOI:10.1111/all.14238] [PMID]
17. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020;395(10229):1054-62. [DOI:10.1016/S0140-6736(20)30566-3]
18. Yu C, Lei Q, Li W, et al. Clinical characteristics, associated factors, and predicting COVID-19 mortality risk: a retrospective study in Wuhan, China. Am J Prevent Med. 2020;59(2):168-75. [DOI:10.1016/j.amepre.2020.05.002] [PMID] [PMCID]
19. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chinese Med J. 2020;133(9):1025. [DOI:10.1097/CM9.0000000000000744] [PMID] [PMCID]
20. Zhu Z, Lian X, Su X, Wu W, Marraro GA, Zeng Y. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res. 2020;21(1):224. [DOI:10.1186/s12931-020-01479-w] [PMID] [PMCID]
21. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506. [DOI:10.1016/S0140-6736(20)30183-5]
22. Li C, Ye J, Chen Q, et al. Elevated lactate dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19. Aging (Albany NY). 2020;12(15):15670. [DOI:10.18632/aging.103770] [PMID] [PMCID]
23. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Europ Respir J. 2020;55(5). [DOI:10.1183/13993003.01227-2020] [PMID] [PMCID]
24. Trecarichi EM, Mazzitelli M, Serapide F, et al. Clinical characteristics and predictors of mortality associated with COVID-19 in elderly patients from a long-term care facility. Sci Rep. 2020;10(1):1-7. [DOI:10.1038/s41598-020-77641-7] [PMID] [PMCID]
25. De Freitas G, Gudur A, Vela-Ortiz M, Jodelka J, Livert D, Krishnamurthy M. Where there is sodium there may be sepsis. J Community hospital internal medicine perspective. 2019;9(4):296-9. [DOI:10.1080/20009666.2019.1634407] [PMID] [PMCID]
26. Schatz V, Neubert P, Schröder A, et al. Elementary immunology: Na+ as a regulator of immunity. Pediatr Nephrol. 2017;32(2):201-10. [DOI:10.1007/s00467-016-3349-x] [PMID] [PMCID]
27. Zhang G, Hu C, Luo L, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127:104364. [DOI:10.1016/j.jcv.2020.104364] [PMID] [PMCID]
28. Chen Z, Wherry EJ. T cell responses in patients with COVID-19. Nature Rev Immunol. 2020;20(9):529-36. [DOI:10.1038/s41577-020-0402-6] [PMID] [PMCID]
29. Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):893-903. [DOI:10.1016/S1470-2045(20)30309-0]
30. Okamoto T, Suzuki K. The role of gap junction-mediated endothelial cell-cell interaction in the crosstalk between inflammation and blood coagulation. Int J Molec Sci. 2017;18(11):2254. [DOI:10.3390/ijms18112254] [PMID] [PMCID]
31. Zheng X, Yang H, Li X, et al. Prevalence of kidney injury and associations with critical illness and death in patients with COVID-19. Clin J Am Soc Nephrol. 2020;15(11):1549-56. [DOI:10.2215/CJN.04780420] [PMID] [PMCID]
32. Wang K, Chen W, Zhou Y-S, Lian J-Q, Zhang Z, Du P, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. biorxiv. 2020. [DOI:10.1101/2020.03.14.988345]
33. Almeida MQ, Mendonca BB. Adrenal insufficiency and glucocorticoid use during the COVID-19 pandemic. Clin. 2020;75.. [DOI:10.6061/clinics/2020/e2022] [PMID] [PMCID]
34. Lin S, Mao W, Zou Q, Lu S, Zheng S. Associations between hematological parameters and disease severity in patients with SARS‐CoV‐2 infection. J Clin Lab Anal. 2021;35(1):e23604. [DOI:10.1002/jcla.23604]
35. Bastug A, Bodur H, Erdogan S, et al. Clinical and laboratory features of COVID-19: Predictors of severe prognosis. Int Immunopharmacol. 2020;88:106950.. [DOI:10.1016/j.intimp.2020.106950] [PMID] [PMCID]
36. Hachim MY, Hachim IY, Naeem KB, Hannawi H, Al Salmi I, Hannawi S. D-dimer, troponin, and urea level at presentation with COVID-19 can predict ICU admission: a single centered study. Front Med. 2020;7. [DOI:10.3389/fmed.2020.585003] [PMID] [PMCID]
37. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-10. [DOI:10.1001/jamacardio.2020.0950] [PMID] [PMCID]
38. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81. [DOI:10.1016/S2213-2600(20)30079-5]

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb